Scholar Rock Holding Co. (NASDAQ:SRRK) Director Sells $34,626.52 in Stock

Scholar Rock Holding Co. (NASDAQ:SRRK) Director Katie Peng sold 1,006 shares of Scholar Rock stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $34.42, for a total value of $34,626.52. Following the completion of the transaction, the director now directly owns 30,319 shares in the company, valued at $1,043,579.98. This represents a 3.21 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Scholar Rock Trading Down 1.8 %

NASDAQ:SRRK opened at $33.05 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The stock’s 50-day moving average is $38.74 and its two-hundred day moving average is $32.04. The stock has a market cap of $3.13 billion, a PE ratio of -14.06 and a beta of 0.59.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Truist Financial lifted their price target on Scholar Rock from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, November 25th. HC Wainwright lifted their price target on Scholar Rock from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Finally, Wedbush reissued an “outperform” rating and issued a $50.00 price target on shares of Scholar Rock in a research note on Monday, March 17th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Scholar Rock currently has an average rating of “Buy” and an average target price of $40.86.

Hedge Funds Weigh In On Scholar Rock

Several institutional investors and hedge funds have recently bought and sold shares of SRRK. GAMMA Investing LLC grew its stake in Scholar Rock by 51.8% during the 4th quarter. GAMMA Investing LLC now owns 788 shares of the company’s stock valued at $34,000 after acquiring an additional 269 shares in the last quarter. Quarry LP lifted its holdings in shares of Scholar Rock by 3,443.3% during the 3rd quarter. Quarry LP now owns 4,500 shares of the company’s stock valued at $36,000 after buying an additional 4,373 shares during the last quarter. Global Retirement Partners LLC lifted its holdings in shares of Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company’s stock valued at $39,000 after buying an additional 766 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Scholar Rock by 1,321.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company’s stock valued at $48,000 after buying an additional 1,031 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Scholar Rock during the 4th quarter valued at about $85,000. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.